Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
FluoGuide raised SEK 104M in a share sale to fund cancer trial development and executive incentives.
FluoGuide A/S raised SEK 104 million in a directed share issue on November 3, 2025, issuing 2.7 million shares at SEK 38 each, 95% of the closing price, to Nordic institutional investors including major shareholders.
The proceeds will fund phase II trials for FG001 in glioma and head and neck cancer, CMC work for a phase III trial, and general operations.
The company also granted 199,000 warrants to executives and board members at SEK 38, with a three-year vesting period and exercise rights until 2035, aiming to align long-term incentives.
Shares will list on Nasdaq First North Growth Market by November 14.
The capital increase raises share capital and results in a 16.69% dilution.
A 90-day lock-up on new issuances and 180-day sales ban for executives support investor confidence.
The credit facility remains at SEK 40 million, extended to April 2027.
FluoGuide recaudó 104 millones de SEK en una venta de acciones para financiar el desarrollo de ensayos oncológicos e incentivos ejecutivos.